[
  {
    "ts": null,
    "headline": "Sightview Expands Leadership Bench, Appointing Vice Presidents of Client Operations and Product Management",
    "summary": "DURHAM, N.C., July 15, 2025--Sightview, the only EHR and practice management partner focused solely on eyecare, has appointed Melissa Wright and Casi Nestelroad as VPs.",
    "url": "https://finnhub.io/api/news?id=36bcf55c4529a9069af34a683403fcce546845d70c72ff5cce0ded40e3d8641f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752601020,
      "headline": "Sightview Expands Leadership Bench, Appointing Vice Presidents of Client Operations and Product Management",
      "id": 135965946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "DURHAM, N.C., July 15, 2025--Sightview, the only EHR and practice management partner focused solely on eyecare, has appointed Melissa Wright and Casi Nestelroad as VPs.",
      "url": "https://finnhub.io/api/news?id=36bcf55c4529a9069af34a683403fcce546845d70c72ff5cce0ded40e3d8641f"
    }
  },
  {
    "ts": null,
    "headline": "Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion",
    "summary": "Cencora (COR) recently executed a distribution services agreement with Citius Oncology, signaling an expansion in its pharmaceutical distribution capabilities. Over the past quarter, Cencora’s share price rose by 4.4%, aligning with the market trend of major indexes reaching record highs. This gain is supported by several corporate actions, including strong second-quarter earnings and ongoing share buybacks, which may have bolstered investor confidence. The dividend announcement and...",
    "url": "https://finnhub.io/api/news?id=db701f6ee1051c2e088cb585641cd24bcd4b983af0e45bef7814c7308e7f862e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752600355,
      "headline": "Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion",
      "id": 135959559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora (COR) recently executed a distribution services agreement with Citius Oncology, signaling an expansion in its pharmaceutical distribution capabilities. Over the past quarter, Cencora’s share price rose by 4.4%, aligning with the market trend of major indexes reaching record highs. This gain is supported by several corporate actions, including strong second-quarter earnings and ongoing share buybacks, which may have bolstered investor confidence. The dividend announcement and...",
      "url": "https://finnhub.io/api/news?id=db701f6ee1051c2e088cb585641cd24bcd4b983af0e45bef7814c7308e7f862e"
    }
  },
  {
    "ts": null,
    "headline": "BD Partners With Waters to Build High-Volume Diagnostics Leader",
    "summary": "BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.",
    "url": "https://finnhub.io/api/news?id=4bcf5f5e012898e050ecb56885d316338fcde4dbb8ff245487958b43cb83af78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752585120,
      "headline": "BD Partners With Waters to Build High-Volume Diagnostics Leader",
      "id": 135960676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.",
      "url": "https://finnhub.io/api/news?id=4bcf5f5e012898e050ecb56885d316338fcde4dbb8ff245487958b43cb83af78"
    }
  },
  {
    "ts": null,
    "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?",
    "summary": "BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.",
    "url": "https://finnhub.io/api/news?id=606184a6dd2df52162878d9f83379e295e7686da3bd04a68ad633601a042bf90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752584520,
      "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?",
      "id": 135959746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.",
      "url": "https://finnhub.io/api/news?id=606184a6dd2df52162878d9f83379e295e7686da3bd04a68ad633601a042bf90"
    }
  }
]